A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 17 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Nov 2023 Planned End Date changed from 31 Oct 2023 to 31 Dec 2023.